Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.

The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...

From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

As Labiotech attented the NLS Days this week, it was the occasion to learn more about the biotech industry in Sweden.

Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for ...

Discover five promising Prader-Willi syndrome therapies climbing the clinical ladder and nearing FDA approval in the coming ...

Complex regional pain syndrome (CRPS) is a rare but severe neuropathic pain condition that causes intense, long-lasting pain, often following an injury or surgery. Patients frequently report some of ...

mRNA vaccine research will be stripped of $500 million in funding from the U.S. Department of Health and Human Services (HHS). The agency listed 22 projects that will be affected, many of which are ...

Antibody therapies constitute a vast global market: currently valued at over $250 billion, the market for antibodies is expected to exceed $850 billion worldwide by 2032. Driving forces behind this ...

In 2020, Novo Nordisk’s Canadian patent for semaglutide, the active ingredient in its blockbuster GLP-1 drugs Ozempic and Wegovy, quietly expired. The reason? A small missed maintenance fee, ...